Most importantly, the AHR is expressed by ER+ and ER− breast cancer cells, and has been found in pre-clinical studies [17], [18] to be an excellent target for the therapy of breast cancer, including triple-negative subtypes (all cell lines examined were AHR+). The gene discussed is AHR; the disease is breast carcinoma.